Biochemistry
1 questionsWhat is the process of Hofmann elimination in organic chemistry?
NEET-PG 2013 - Biochemistry NEET-PG Practice Questions and MCQs
Question 81: What is the process of Hofmann elimination in organic chemistry?
- A. E1 elimination reaction favoring tertiary substrates
- B. E2 elimination reaction producing the least substituted alkene (Correct Answer)
- C. SN1 substitution reaction with carbocation intermediate
- D. SN2 substitution reaction with inversion of configuration
Explanation: ***E2 elimination reaction producing the least substituted alkene*** - **Hofmann elimination** is a type of **E2 elimination** reaction where a **quaternary ammonium salt** is heated in the presence of a strong base. - Unlike most E2 reactions which follow **Zaitsev's rule** (producing the most substituted alkene), Hofmann elimination follows the **Hofmann rule**, leading to the formation of the **least substituted (least stable) alkene**. *SN1 substitution reaction with carbocation intermediate* - **SN1 reactions** involve the formation of a **carbocation intermediate** and are typically substitution reactions, not elimination. - Hofmann elimination is an elimination reaction and does not proceed through a carbocation intermediate. *E1 elimination reaction favoring tertiary substrates* - **E1 reactions** are a two-step process involving a **carbocation intermediate** and generally favor **tertiary substrates** and produce the **Zaitsev product**. - Hofmann elimination is a concerted, one-step E2 mechanism and does not involve carbocations. *SN2 substitution reaction with inversion of configuration* - **SN2 reactions** are **bimolecular nucleophilic substitution** reactions that occur in a single step with **inversion of configuration** at the carbon center. - Hofmann elimination is an elimination process resulting in an alkene, not a substitution product, and does not involve inversion of configuration at a stereocenter.
Internal Medicine
1 questionsThalassemia gives protection against ?
NEET-PG 2013 - Internal Medicine NEET-PG Practice Questions and MCQs
Question 81: Thalassemia gives protection against ?
- A. Protection against filaria
- B. Protection against kala-azar
- C. Protection against leptospirosis
- D. Protection against malaria (Correct Answer)
Explanation: Protection against malaria - Individuals with thalassemia, particularly thalassemia trait, have some degree of protection against severe forms of malaria, specifically Plasmodium falciparum [1]. - The altered red blood cell structure and reduced hemoglobin content in thalassemia make the red blood cells less hospitable for the parasites, hindering their replication and survival [1]. Protection against filaria - Filaria is caused by parasitic worms (nematodes) transmitted by mosquitoes, leading to lymphatic filariasis (elephantiasis) or onchocerciasis (river blindness). - Thalassemia's primary impact is on red blood cell health and oxygen transport, offering no known protective effect against nematode infections or their associated pathology. Protection against kala-azar - Kala-azar (visceral leishmaniasis) is caused by Leishmania parasites transmitted by sandflies, primarily affecting the reticuloendothelial system (spleen, liver, bone marrow). - There is no established scientific evidence indicating that thalassemia provides protection against Leishmania infections or their clinical manifestations. Protection against leptospirosis - Leptospirosis is a bacterial infection caused by Leptospira bacteria, typically acquired through contact with contaminated water or animal urine. - Thalassemia is a genetic blood disorder; its physiological effects are unrelated to the mechanisms of infection or immunity against bacterial pathogens like Leptospira.
Pharmacology
8 questionsWhich of the following is not a cardioselective beta blocker?
Which dopamine receptor is known for its inhibitory action in the central nervous system?
Which of the following statements about clonidine is incorrect?
Which urinary bladder spasmolytic has local anesthetic properties?
Which of the following is not a recognized use of alpha-2-agonists?
When two different chemicals act on two different receptors and their responses are opposite to each other on the same cell, this phenomenon is called?
Which of the following is classified as a Type E adverse reaction?
In the context of pharmacology, which plasma protein do acidic drugs primarily bind to?
NEET-PG 2013 - Pharmacology NEET-PG Practice Questions and MCQs
Question 81: Which of the following is not a cardioselective beta blocker?
- A. Nebivolol
- B. Atenolol
- C. Betaxolol
- D. Oxprenolol (Correct Answer)
Explanation: ***Oxprenolol*** - **Oxprenolol** is a non-selective beta-blocker with **intrinsic sympathomimetic activity (ISA)**, meaning it blocks both β1 and β2 receptors and partially stimulates them. - Its non-selective action means it affects both the heart (β1) and other organs like the lungs (β2), making it less suitable for patients with respiratory conditions. *Nebivolol* - **Nebivolol** is a highly cardioselective beta-blocker that primarily blocks **β1 receptors** and also has **vasodilatory properties** due to nitric oxide release. - Its high selectivity translates to fewer β2-mediated side effects, such as bronchoconstriction. *Atenolol* - **Atenolol** is a **cardioselective beta-blocker** that predominantly blocks **β1 receptors** at therapeutic doses. - This selectivity makes it a common choice for cardiovascular conditions, reducing the risk of bronchospasm compared to non-selective agents. *Betaxolol* - **Betaxolol** is a **cardioselective beta-blocker** primarily used for the treatment of hypertension and glaucoma. - It selectively blocks **β1 adrenergic receptors**, minimizing effects on the lungs compared to non-selective beta-blockers.
Question 82: Which dopamine receptor is known for its inhibitory action in the central nervous system?
- A. Dopamine Receptor D5
- B. No inhibitory dopamine receptor present
- C. Dopamine Receptor D2 (Correct Answer)
- D. Dopamine Receptor D1
Explanation: ***Dopamine Receptor D2*** - The **D2 receptor** is a member of the D2-like family (D2, D3, D4), which are **G-protein coupled receptors** that inhibit adenylyl cyclase activity. - Its activation typically leads to a **decrease in neuronal excitability** and neurotransmitter release, providing an inhibitory effect in the CNS. *Dopamine Receptor D5* - The **D5 receptor** belongs to the D1-like family (D1, D5), which are **G-protein coupled receptors** that stimulate adenylyl cyclase activity. - Activation of D5 receptors typically leads to **excitatory effects** rather than inhibitory ones in the CNS. *No inhibitory dopamine receptor present* - This statement is incorrect as specific dopamine receptor subtypes, particularly the **D2-like family**, are well-established to exert inhibitory actions in the CNS. - These inhibitory effects are crucial for various physiological processes, including motor control and reward pathways. *Dopamine Receptor D1* - The **D1 receptor** is part of the D1-like family (D1, D5) and is known for its **excitatory effects** in the CNS. - Activation of D1 receptors leads to an **increase in intracellular cAMP** and generally enhances neuronal activity.
Question 83: Which of the following statements about clonidine is incorrect?
- A. Alpha 2 receptor agonist
- B. Sudden withdrawal causes rebound hypertension
- C. Controls loose motions due to diabetic neuropathy
- D. First line for AMI (Correct Answer)
Explanation: ***First line for AMI*** - Clonidine is **not first-line** for **Acute Myocardial Infarction (AMI)** as it can cause **bradycardia** and **hypotension**, potentially worsening cardiac output. - First-line AMI treatments include **thrombolytics**, **antiplatelet agents** (aspirin), **beta-blockers**, and **ACE inhibitors** for optimal cardiac protection. *Alpha 2 receptor agonist* - Clonidine is indeed an **alpha-2 adrenergic receptor agonist** that acts centrally in the **medulla oblongata**. - It reduces **sympathetic outflow** from the CNS, leading to decreased **heart rate**, **blood pressure**, and **peripheral vascular resistance**. *Sudden withdrawal causes rebound hypertension* - Abrupt clonidine discontinuation causes dangerous **rebound hypertension** due to sudden loss of **sympathetic inhibition**. - **Gradual tapering** over 1-2 weeks is essential to prevent this potentially life-threatening complication. *Controls loose motions due to diabetic neuropathy* - Clonidine effectively treats **diabetic diarrhea** by stimulating **alpha-2 receptors** in the enteric nervous system. - It **slows intestinal transit** and **enhances fluid absorption**, making it useful for **autonomic neuropathy-related** gastrointestinal symptoms.
Question 84: Which urinary bladder spasmolytic has local anesthetic properties?
- A. Tamsulosin
- B. Terazosin
- C. Oxybutynin (Correct Answer)
- D. Yohimbine
Explanation: ***Oxybutynin*** - Possesses both **anticholinergic properties** (bladder smooth muscle relaxation) and **direct local anesthetic properties**, which contribute to its spasmolytic effect on the detrusor muscle. - The **local anesthetic action** directly reduces bladder detrusor muscle contractions, explaining its efficacy in treating urge incontinence and overactive bladder. - This dual mechanism makes it unique among bladder spasmolytics. *Tamsulosin* - Is an **alpha-1 adrenergic receptor blocker** used for benign prostatic hyperplasia (BPH) by relaxing smooth muscle in the prostate and bladder neck. - Does **not have local anesthetic properties** and is not a bladder detrusor spasmolytic. *Terazosin* - Also an **alpha-1 adrenergic receptor blocker**, similar to tamsulosin, used for BPH and hypertension. - Acts via **vascular and prostatic smooth muscle relaxation**, without local anesthetic or bladder spasmolytic effects. *Yohimbine* - Is an **alpha-2 adrenergic receptor antagonist** known for increasing sympathetic outflow. - Does **not have bladder spasmolytic effects** or local anesthetic properties.
Question 85: Which of the following is not a recognized use of alpha-2-agonists?
- A. Glaucoma
- B. Hypertension
- C. Sedation
- D. Benign Hyperplasia of prostate (Correct Answer)
Explanation: ***Correct Answer: Benign Hyperplasia of prostate*** - Alpha-2-agonists are **NOT** used to treat **benign prostatic hyperplasia (BPH)**; this condition is typically managed with **alpha-1-blockers** (e.g., tamsulosin, alfuzosin) or 5-alpha-reductase inhibitors. - Alpha-1-blockers relax the smooth muscle in the prostate and bladder neck, improving urine flow, which involves a different receptor mechanism than alpha-2-agonists. - Alpha-2-agonists would not provide therapeutic benefit for BPH. *Incorrect: Glaucoma* - Alpha-2-agonists (e.g., **brimonidine**, **apraclonidine**) **are** used to treat **glaucoma** by reducing aqueous humor production and increasing uveoscleral outflow. - This action helps to **lower intraocular pressure**, a primary goal in glaucoma management. *Incorrect: Hypertension* - Central-acting alpha-2-agonists (e.g., **clonidine**, **methyldopa**) **are** used as **antihypertensive agents**. - They reduce sympathetic outflow from the central nervous system, leading to decreased heart rate, vasodilation, and consequently, **lower blood pressure**. *Incorrect: Sedation* - Alpha-2-agonists like **dexmedetomidine** and **clonidine** **are** commonly used for **sedation** in critically ill patients, especially in intensive care units. - They produce sedation, analgesia, and anxiolysis without causing significant respiratory depression, making them valuable in certain clinical settings.
Question 86: When two different chemicals act on two different receptors and their responses are opposite to each other on the same cell, this phenomenon is called?
- A. Physiological antagonism (Correct Answer)
- B. Chemical antagonism
- C. Reversible antagonism
- D. Competitive antagonism
Explanation: ***Physiological antagonism*** - This occurs when two drugs act on **different receptors** to produce **opposite physiological effects** within the same system or cell, effectively canceling each other out [1]. - A classic example is the opposing actions of **histamine** (causing bronchoconstriction) and **adrenaline** (causing bronchodilation) on the bronchi [1]. *Chemical antagonism* - This involves a direct **chemical interaction** between two drugs that results in the **inactivation of one or both** of them. - An example is the binding of **chelating agents** to heavy metals, forming an inert complex. *Reversible antagonism* - This describes antagonism where the antagonist binds to the receptor and can be **displaced by a higher concentration of the agonist**. - It does not specifically describe antagonists acting on different receptors or producing opposing physiological effects. *Competitive antagonism* - This occurs when an antagonist directly **competes with an agonist for the same binding site** on a receptor [1]. - The antagonist, while not producing a response itself, prevents the agonist from binding and activating the receptor.
Question 87: Which of the following is classified as a Type E adverse reaction?
- A. Toxicity
- B. Augmented effect
- C. Teratogenesis
- D. Rebound effect due to drug withdrawal (Correct Answer)
Explanation: ***Rebound effect due to drug withdrawal*** - Type E adverse reactions are related to **end-of-treatment effects**, specifically withdrawal phenomena. - The **rebound effect** after drug cessation, such as worsened angina after stopping beta-blockers, is a classic example of a Type E reaction. *Toxicity* - This is a general term for adverse effects from excessive drug doses and is **not a specific type** in the ABCDEF classification. - Dose-dependent toxic effects typically align with **Type A** (augmented) reactions, which are predictable and related to the drug's pharmacology. *Augmented effect* - An **augmented effect** is classified as a Type A adverse drug reaction, meaning it is **dose-dependent**, predictable from the drug's known pharmacology, and common. - Examples include bleeding with anticoagulants or hypotension with antihypertensives. *Teratogenesis* - **Teratogenesis** refers to drug-induced fetal malformations and is categorized as a **Type D** (delayed) adverse drug reaction. - These effects are often severe, occur after prolonged exposure, and are rare.
Question 88: In the context of pharmacology, which plasma protein do acidic drugs primarily bind to?
- A. Globulin
- B. Albumin (Correct Answer)
- C. α1-acid glycoprotein
- D. None of the options
Explanation: ***Albumin*** - **Albumin** is the most abundant plasma protein and has multiple binding sites for a wide range of drugs, particularly **acidic drugs**. - Its high concentration and diverse binding capabilities make it the primary transporter for many **lipophilic** and **anionic drugs**. *Globulin* - **Globulins** are a diverse group of proteins, some of which bind to drugs, but they primarily transport **hormones**, **metals**, and **vitamins**, not acidic drugs. - They are less significant for binding acidic drugs compared to albumin. *α1-acid glycoprotein* - **α1-acid glycoprotein** primarily binds to **basic drugs** due to its numerous acidic residues. - While it plays a crucial role in binding basic compounds, it has limited affinity for acidic drugs. *None of the options* - This option is incorrect because **albumin** is a well-established and significant plasma protein for binding acidic drugs. - Specific plasma proteins are known to bind different types of drugs, and for acidic drugs, albumin is the primary binder.